跳至主要内容
临床试验/NCT01860820
NCT01860820已完成不适用

The Effect of Neuromuscular Stimulation on Post-Transplant Leg Edema

Lawson Health Research Institute2 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2015年6月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
100
试验地点
2
主要终点
Decrease in edema

研究概览

简要总结

This will be a randomized, controlled trial involving kidney and kidney pancreas transplant patients. There will be 2 groups and patients that will be randomized to one of the two groups. Clinical outcomes will be compared for those in each group and clinical differences between patients who receive routine medical therapy with IPC/TEDS versus the Geko device will also be evaluated.

详细描述

This will be a randomized, controlled trial involving kidney and kidney pancreas transplant patients. There will be 2 groups and patients will be randomized to one of the two; one will receive standard of care IPC or TED stockings to help with circulation, the other group will use the geko device which is a newer device with Health Canada approval. Clinical outcomes will be compared for those in each group and clinical differences between patients who receive routine medical therapy with IPC/TEDS versus the Geko device will also be evaluated.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female
  • At least 18 years old
  • Undergoing kidney or kidney pancreas transplant surgery as the recipient
  • Able and willing to provide written informed consent
  • Absence of known peripheral vascular disease
  • Body Mass Index of between 18 and 34
  • Leg circumference at site of geko™ device placement is 24" or less

排除标准

  • History of deep vein thrombosis
  • Temporary or permanent cardiac pacing
  • Patient is pregnant
  • Any patient which may be excluded by way of warnings in the Manufacturer's Instructions for Use
  • Any patient who requires an ECG electrode applied on the leg for continuous monitoring throughout therapy
  • Previous leg(s) amputation
  • Presence of any of the following in the site of intended device placement: cancerous lesion, swollen or infected or inflamed areas or skin eruptions i.e. phlebitis, thrombophlebitis, varicose veins
  • History or signs of haematological disorders (especially in relation to clotting or coagulation disorders) including presence or history of thrombus formation
  • BMI index >36
  • Patients with any neurological disorder or disease that would interfere with proper assessment and or conduct of the trial
  • History of implantable brain or other stimulator
  • Patients who can not tolerate the stimulation from the GEKO device

结局指标

主要结局

Decrease in edema

时间窗: Within 30 days post-transplant

As measured by patient weight and leg diameter

次要结局

  • Patient satisfaction(3 and 6 days after transplant)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验